Target attainment of extended-interval dosing of tobramycin in patients less than five years of age with cystic fibrosis: A pharmacokinetic analysis
Kevin J Downes, Austyn Grim, Laura Shanley, Ronald C Rubenstein, Athena F Zuppa, Marc R. Gastonguay
doi: https://doi.org/10.1101/2022.01.02.22268643
Kevin J Downes
1Division of Infectious, Children’s Hospital of Philadelphia, Philadelphia, PA
2Center for Clinical Pharmacology, Children’s Hospital of Philadelphia, Philadelphia, PA
3Center for Pediatric Clinical Effectiveness, Children’s Hospital of Philadelphia, Philadelphia, PA
4Department of Pediatrics, The University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
MDAustyn Grim
5Department of Pharmacy, Texas Children’s Hospital, Houston, TX
PharmD, BCPPSLaura Shanley
6Clinical Pharmacy, Children’s Hospital of Philadelphia, Philadelphia, PA
PharmDRonald C Rubenstein
7Division of Allergy and Pulmonary Medicine, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO
MD, PhDAthena F Zuppa
2Center for Clinical Pharmacology, Children’s Hospital of Philadelphia, Philadelphia, PA
8Division of Critical Care Medicine, Children’s Hospital of Philadelphia, Philadelphia, PA
9Department of Anesthesiology and Critical Care, The University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
MD, MSCEMarc R. Gastonguay
10Metrum Research Group, Tariffville, CT
PhD![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Article usage
Posted January 03, 2022.
Target attainment of extended-interval dosing of tobramycin in patients less than five years of age with cystic fibrosis: A pharmacokinetic analysis
Kevin J Downes, Austyn Grim, Laura Shanley, Ronald C Rubenstein, Athena F Zuppa, Marc R. Gastonguay
medRxiv 2022.01.02.22268643; doi: https://doi.org/10.1101/2022.01.02.22268643
Target attainment of extended-interval dosing of tobramycin in patients less than five years of age with cystic fibrosis: A pharmacokinetic analysis
Kevin J Downes, Austyn Grim, Laura Shanley, Ronald C Rubenstein, Athena F Zuppa, Marc R. Gastonguay
medRxiv 2022.01.02.22268643; doi: https://doi.org/10.1101/2022.01.02.22268643
Subject Area
Subject Areas
- Addiction Medicine (339)
- Allergy and Immunology (665)
- Anesthesia (179)
- Cardiovascular Medicine (2621)
- Dermatology (220)
- Emergency Medicine (396)
- Epidemiology (12161)
- Forensic Medicine (10)
- Gastroenterology (754)
- Genetic and Genomic Medicine (4053)
- Geriatric Medicine (383)
- Health Economics (674)
- Health Informatics (2616)
- Health Policy (996)
- Hematology (359)
- HIV/AIDS (839)
- Medical Education (397)
- Medical Ethics (109)
- Nephrology (429)
- Neurology (3823)
- Nursing (208)
- Nutrition (569)
- Oncology (2004)
- Ophthalmology (580)
- Orthopedics (238)
- Otolaryngology (303)
- Pain Medicine (250)
- Palliative Medicine (73)
- Pathology (470)
- Pediatrics (1106)
- Primary Care Research (445)
- Public and Global Health (6493)
- Radiology and Imaging (1384)
- Respiratory Medicine (868)
- Rheumatology (399)
- Sports Medicine (338)
- Surgery (440)
- Toxicology (52)
- Transplantation (185)
- Urology (165)